Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Income (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Operating Income data on record, last reported at -$33.7 million in Q3 2025.

  • For Q3 2025, Operating Income rose 34.41% year-over-year to -$33.7 million; the TTM value through Sep 2025 reached -$165.3 million, up 21.03%, while the annual FY2024 figure was -$191.2 million, 36.16% up from the prior year.
  • Operating Income reached -$33.7 million in Q3 2025 per ZNTL's latest filing, up from -$36.1 million in the prior quarter.
  • Across five years, Operating Income topped out at -$24.8 million in Q1 2024 and bottomed at -$103.9 million in Q2 2023.
  • Average Operating Income over 4 years is -$55.6 million, with a median of -$54.2 million recorded in 2022.
  • Peak YoY movement for Operating Income: skyrocketed 61.87% in 2024, then tumbled 84.22% in 2025.
  • A 4-year view of Operating Income shows it stood at -$51.8 million in 2022, then tumbled by 31.24% to -$67.9 million in 2023, then rose by 26.61% to -$49.8 million in 2024, then skyrocketed by 32.33% to -$33.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$33.7 million in Q3 2025, -$36.1 million in Q2 2025, and -$45.6 million in Q1 2025.